1
|
Lago-Sampedro A, Oualla-Bachiri W, García-Serrano S, Maldonado-Araque C, Valdés S, Doulatram-Gamgaram V, Olveira G, Delgado E, Chaves FJ, Castaño L, Calle-Pascual A, Franch-Nadal J, Rojo-Martínez G, García-Escobar E. Protective Effect of High Adherence to Mediterranean Diet on the Risk of Incident Type-2 Diabetes in Subjects with MAFLD: The Di@bet.es Study. Nutrients 2024; 16:3788. [PMID: 39519621 PMCID: PMC11548257 DOI: 10.3390/nu16213788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2024] [Revised: 10/28/2024] [Accepted: 10/31/2024] [Indexed: 11/16/2024] Open
Abstract
Background/Objectives: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) increases the risk of Type-2 Diabetes (T2DM). The Mediterranean diet (MD) has shown advantages in the management of MAFLD and preventing co-morbidities; however, its relationship with T2DM development in MAFLD has been less investigated. We aimed to evaluate the association of MD adherence with the risk of incident T2DM in the Spanish adult population with MAFLD and according to their weight gain at 7.5 years follow-up. Methods: A cohort of 714 participants (without weight increment: 377; with weight increment: 337) from the Di@bet.es cohort study with MAFLD and without T2DM at baseline were investigated. Anthropometric, sociodemographic, clinical data, and a survey on habits were recorded. OGTT and fasting blood biochemistry determinations were made. Baseline adherence to MD was estimated by the adapted 14-point MEDAS questionnaire and categorized as high and low adherence. Results: In total, 98 people developed T2DM at follow-up. The high adherence to MD was inversely associated with the development of T2DM in both the overall population (0.52 [0.31-0.87]) and subjects without weight gain at follow-up (0.35 [0.16-0.78]). Conclusions: Our results suggest the protective effect of high adherence to MD regarding the risk of T2DM in subjects with MAFLD, with this health benefit being more evident in men with the absence of weight gain. These results support the recommendations for MD use in these patients.
Collapse
Affiliation(s)
- Ana Lago-Sampedro
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, IBIMA Plataforma BIONAND, 29009 Málaga, Spain
- Departamento de Medicina y Dermatología, Universidad de Málaga-UMA, 29071 Málaga, Spain
| | - Wasima Oualla-Bachiri
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, IBIMA Plataforma BIONAND, 29009 Málaga, Spain
- Departamento de Medicina y Dermatología, Universidad de Málaga-UMA, 29071 Málaga, Spain
| | - Sara García-Serrano
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, IBIMA Plataforma BIONAND, 29009 Málaga, Spain
| | - Cristina Maldonado-Araque
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, IBIMA Plataforma BIONAND, 29009 Málaga, Spain
| | - Sergio Valdés
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, IBIMA Plataforma BIONAND, 29009 Málaga, Spain
| | - Viyey Doulatram-Gamgaram
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, IBIMA Plataforma BIONAND, 29009 Málaga, Spain
- Departamento de Medicina y Dermatología, Universidad de Málaga-UMA, 29071 Málaga, Spain
| | - Gabriel Olveira
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, IBIMA Plataforma BIONAND, 29009 Málaga, Spain
| | - Elias Delgado
- Centro de Investigaciónn Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain;
- Department of Endocrinology and Nutrition, Health Research Institute of the Principality of Asturias (ISPA), Central University Hospital of Asturias, University of Oviedo, 33011 Oviedo, Spain
| | - Felipe Javier Chaves
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- Genomic and Genetic Diagnosis Unit, INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
| | - Luis Castaño
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- Centro de Investigaciónn Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain;
- Biobizkaia Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, CIBERDEM, CIBERER, Endo-ERN, 48903 Barakaldo, Spain
| | - Alfonso Calle-Pascual
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- Department of Endocrinology and Nutrition, San Carlos University Hospital of Madrid, 28040 Madrid, Spain
| | - Josep Franch-Nadal
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- EAP Raval Sud, Catalan Institute of Health, GEDAPS Network, Primary Care, Research Support Unit (IDIAP—Jordi Gol Foundation), 08001 Barcelona, Spain
| | - Gemma Rojo-Martínez
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, IBIMA Plataforma BIONAND, 29009 Málaga, Spain
| | - Eva García-Escobar
- Centro de Investigaciónn Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain (F.J.C.); (A.C.-P.); (J.F.-N.)
- UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, IBIMA Plataforma BIONAND, 29009 Málaga, Spain
| |
Collapse
|
2
|
Loosen SH, Killer A, Luedde T, Roderburg C, Kostev K. Helicobacter pylori infection associated with an increased incidence of cholelithiasis: A retrospective real-world cohort study of 50 832 patients. J Gastroenterol Hepatol 2024; 39:1809-1815. [PMID: 38714499 DOI: 10.1111/jgh.16597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 04/07/2024] [Accepted: 04/21/2024] [Indexed: 05/10/2024]
Abstract
BACKGROUND AND AIM Helicobacter pylori (H. pylori) infection is a bacterial disease of the stomach that has been associated with an increased incidence of cholelithiasis. While the updated German guideline emphasizes the relevance of H. pylori as a pathogen and recommends eradication therapy, systematic data on the association between H. pylori infection, its eradication, and the subsequent diagnosis of cholelithiasis in Germany are missing. METHODS A total of 25 416 patients with and 25 416 propensity score-matched individuals without H. pylori infection were identified from the Disease Analyzer database (IQVIA) between 2005 and 2021. A subsequent diagnosis of cholelithiasis was analyzed as a function of H. pylori infection as well as its eradication using Cox regression models. RESULTS After 10 years of follow-up, 8.0% versus 5.8% of patients with and without H. pylori infection were diagnosed with cholelithiasis (P < 0.001). Regression analysis revealed a significant association between H. pylori infection and cholelithiasis (hazard ratio [HR]: 1.45; 95% confidence interval [CI]: 1.33-1.58), which was stronger in men (HR: 1.63; 95% CI: 1.41-1.90) than in women (HR: 1.36; 95% CI: 1.22-1.52). In terms of eradication therapy, both an eradicated H. pylori infection (HR: 1.48; 95% CI: 1.31-1.67) and a non-eradicated H. pylori infection (HR: 1.41; 95% CI: 1.25-1.60) were associated with a subsequent diagnosis of cholelithiasis. CONCLUSION The present study reveals a strong association between H. pylori infection and a subsequent diagnosis of cholelithiasis in a large real-world cohort from Germany. Eradication therapy was not associated with a reduced incidence of cholelithiasis in our cohort.
Collapse
Affiliation(s)
- Sven H Loosen
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Alexander Killer
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Tom Luedde
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Christoph Roderburg
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Karel Kostev
- Department of Epidemiology, IQVIA, Frankfurt, Germany
| |
Collapse
|
3
|
Wang Q, Liu K, Zhang T, Wang T, Li H, Wang C, Chen J, Ren L. TG: A Mediator of the Relationship of Serum Uric Acid to Creatinine Ratio and Nonalcoholic Fatty Liver Disease in Non-Obese Patients with Type 2 Diabetes. Diabetes Metab Syndr Obes 2024; 17:913-923. [PMID: 38435633 PMCID: PMC10908273 DOI: 10.2147/dmso.s451852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2023] [Accepted: 02/19/2024] [Indexed: 03/05/2024] Open
Abstract
Background The study estimated the association between NAFLD and SUA/Cr in Chinese non-obese patients with type 2 diabetes mellitus (T2DM) and also investigated mediating effect of TG. Methods All patients were divided into NAFLD group (n = 420) and non-NAFLD group (n = 347). The differences of biochemical indicators between the two groups were compared. The link between SUA/Cr and other parameters was checked through Spearman correlation analysis. Differences in the incidence rate of NAFLD between SUA/Cr and TG 3 tertile subgroups were tested by chi-squared. To explore the independent influence of SUA/Cr and TG on NAFLD, logistic regression was performed. The predictive value of SUA/Cr and SUA/Cr combined with BMI for NAFLD was analyzed using ROC curves. In addition, to confirm whether TG has a mediating effect on the link of SUA/Cr and NAFLD, we conducted a mediating analysis. Results NAFLD group had higher SUA/Cr values than individuals without NAFLD (P < 0.01). SUA/Cr was linked with TC and TG (r = 0.081, 0.215 respectively). NAFLD prevalence increased progressively from quartile 1 to quartile 3 of SUA/Cr (44% vs 57% vs 62%). Prevalence of NAFLD increased from quartile 1 to quartile 3 of TG (35.8% vs 58.7% vs 69.9%). Analysis of the logistic regression revealed that SUA/Cr and TG were statistically linked with NAFLD. The ROC curve pointed out that the area under the curve (AUC), sensitivity and specificity of SUA/Cr were 0.59, 0.629 and 0.522, respectively. The AUC, sensitivity and specificity for SUA/Cr combined with BMI were 0.719, 0.644 and 0.677, separately. The mediation analysis showed a statistically direct effect of SUA/Cr on NAFLD (β=0.148, 95% CI: 0.0393, 0.2585). The function of SUA/Cr on NAFLD partially mediated by TG (β=0.1571, 95% CI: 0.0704, 0.2869). Conclusion SUA/Cr was significantly associated with NAFLD in non-obese T2DM patients, and TG partially mediated this association. SUA/Cr can be applied to predict for NAFLD.
Collapse
Affiliation(s)
- Qing Wang
- Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China
| | - Ke Liu
- Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China
| | - Tian Zhang
- Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China
| | - Ting Wang
- Department of Clinical laboratory, Nanjing Medical College, Nanjing, Jiangsu, People’s Republic of China
| | - Huan Li
- Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China
| | - Chang Wang
- Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China
| | - Jinhu Chen
- Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China
| | - Luping Ren
- Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China
| |
Collapse
|
4
|
Kosmalski M, Szymczak-Pajor I, Drzewoski J, Śliwińska A. Non-Alcoholic Fatty Liver Disease Is Associated with a Decreased Catalase (CAT) Level, CT Genotypes and the T Allele of the -262 C/T CAT Polymorphism. Cells 2023; 12:2228. [PMID: 37759451 PMCID: PMC10527641 DOI: 10.3390/cells12182228] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2023] [Revised: 08/18/2023] [Accepted: 08/30/2023] [Indexed: 09/29/2023] Open
Abstract
BACKGROUND It is well known that oxidative stress plays an important role in the development of non-alcoholic fatty liver disease (NAFLD). It has been suggested that an insufficient antioxidant defense system composed of antioxidant enzymes, including catalase (CAT) and nonenzymatic molecules, is a key factor triggering oxidative damage in the progression of liver disease. Therefore, the aim of our study was to assess whether the level of CAT and -262 C/T polymorphism in the promoter of CAT (rs1001179) are associated with NAFLD. METHODS In total, 281 adults (152/129 female/male, aged 65.61 ± 10.44 years) were included in the study. The patients were assigned to an NAFLD group (n = 139) or a group without NAFLD (n = 142) based on the results of an ultrasound, the Hepatic Steatosis Index, and the Fatty Liver Index (FLI). CAT levels were determined using an ELISA test, and genomic DNA was extracted via the standard phenol/chloroform-based method and genotyped via RFLP-PCR. RESULTS The CAT level was decreased in NAFLD patients (p < 0.001), and an ROC analysis revealed that a CAT level lower than 473.55 U/L significantly increases the risk of NAFLD. In turn, genotyping showed that the CT genotype and the T allele of -262 C/T CAT polymorphism elevate the risk of NAFLD. The diminished CAT level in the NAFLD group correlated with increased FLI, waist circumference and female gender. CONCLUSION The obtained results support observations that oxidative damage associated with NAFLD may be the result of a decreased CAT level as a part of the antioxidant defense system.
Collapse
Affiliation(s)
- Marcin Kosmalski
- Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland
| | - Izabela Szymczak-Pajor
- Department of Nucleic Acid Biochemistry, Medical University of Lodz, 92-213 Lodz, Poland; (I.S.-P.); (A.Ś.)
| | - Józef Drzewoski
- Central Teaching Hospital of Medical University of Lodz, 92-213 Lodz, Poland;
| | - Agnieszka Śliwińska
- Department of Nucleic Acid Biochemistry, Medical University of Lodz, 92-213 Lodz, Poland; (I.S.-P.); (A.Ś.)
| |
Collapse
|